Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 6/20 | 0.44 |
| ▸ | PRKDC | P78527 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16616316 | 0.85 | LMNA (0.48) | ALDH1A1KDM4ETSHRHPGDMEN1 | |
| SCHEMBL16055950 | 0.83 | PRKDC (0.46) | ERN1PRKDCALDH1A1KDM4ETSHR | |
| SCHEMBL4600427 | 0.80 | ALDH1A1 (0.57) | ERN1PRKDCALDH1A1KDM4ETSHR | |
| SCHEMBL30316242 | 0.80 | ALDH1A1 (0.57) | ERN1PRKDCALDH1A1KDM4ETSHR | |
| SCHEMBL17535544 | 0.79 | ERN1 (0.41) | ERN1ALDH1A1KDM4ETSHRTDP1 | |
| SCHEMBL22918396 | 0.78 | PRKDC (0.63) | ERN1PRKDCALDH1A1KDM4ETSHR | |
| SCHEMBL16055178 | 0.78 | ERN1 (0.45) | ERN1PRKDCALDH1A1KDM4ETSHR | |
| SCHEMBL17535470 | 0.77 | ERN1 (0.53) | ERN1ALDH1A1KDM4ETSHRTDP1 | |
| SCHEMBL16616057 | 0.76 | ERN1 (0.37) | ERN1PRKDCALDH1A1AMY1AHPGD | |
| SCHEMBL1539323 | 0.75 | ALDH1A1 (0.69) | ERN1PRKDCALDH1A1KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970331-B1 | SPIRO AZETIDINE ISOXAZOLE DERIVATIVES AND THEIR USE AS SSTR5 ANTAGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-05-17 | — | — | EP | disclosed |
| US-9605000-B2 | Spiro azetidine isoxazole derivatives and their use as SSTR antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-28 | — | — | US | disclosed |
| US-20160060273-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060273-A1 | HETEROCYCLIC COMPOUND | SSTR5, SSTR1, SSTR2 | ERN1 3034/4885PRKDC 4153/4885ALDH1A1 2449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.